SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Part ...

First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAHSAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic con ...

Company Overview - Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) specializes in developing oral drugs for rare hormonal diseases and tumors, with its lead candidate, Paltusotine, currently in Phase 3 trials for acromegaly and carcinoid syndrome [2] - The company's portfolio also includes treatments for conditions such as Cushing's disease and obesity [2] Investment Insights - Jim Cramer highlighted CRNX as a stock to consider, noting that Goldman Sachs has issued a Buy recommendation, indicating a positive outlook from a major financial firm [1] - Cramer emphasized that CRNX, priced at $55, is a more substantial investment compared to lower-priced stocks, suggesting that investors should focus on the company's fundamentals rather than just the stock price [1]

Company Overview - Amprius Technologies specializes in high-energy-density, high-capacity lithium-ion batteries utilizing silicon anodes, positioning itself to lead in the electric power economy shift [2][6] - The company claims to offer batteries with the highest energy density on the market, long life cycles, and ultra-fast charging times, while ensuring safety through rigorous testing [1][6] Financial Performance - In its 3Q25 report, Amprius reported a record revenue of $21.4 million, exceeding forecasts by $4.6 million, and reflecting a 172% year-over-year increase [8] - The company experienced a net loss of 3 cents per share, which was better than expected, and its stock has risen 187.5% over the past 12 months [8] Product Features - Amprius batteries provide 100% longer running times, operate within a temperature range of -30 to +60 degrees Celsius, support over 1,300 lifetime charge cycles, and can charge to 80% capacity in just 6 minutes [6] - The batteries are designed for diverse applications, including manned and unmanned aircraft, light electric vehicles, and AI and robotics [6] Leadership Transition - As of January 1, Tom Stepien has taken over as CEO, transitioning from his previous role as President, while former CEO Dr. Kang Sun remains as an Executive Advisor [7] Market Position and Strategy - Analyst Colin Rusch notes that Amprius is entering a new phase with a focus on long-term pricing strategies and has over 2GWh of manufacturing capacity, which aligns with the US National Defense Authorization Act [9] - The company is expected to announce significant new customers, leveraging its lead in high-density, lightweight battery technology for aerospace and defense applications [9] Analyst Ratings - Rusch rates AMPX stock as Outperform (Buy) with a price target of $17, indicating a potential one-year gain of 67.5% [10] - The stock has a Strong Buy consensus based on 7 positive reviews, with an average target price suggesting a 69% upside [10]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the 14 best booming stocks to buy right now. On January 12, Goldman Sachs analyst Richard Law upgraded the stock’s rating to Buy from Neutral, with a share price target of $67. Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral The adjustment followed promising results from a trial investigating the impact of atumelnant on congenital adrenal hyperplasia (CAH). The findings revealed a 67% reduction in A4 in Cohort 4, rep ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Commercial Execution and Market Potential - Palsonify demonstrated strong commercial execution with robust metrics, indicating a successful launch strategy[5] - The estimated acromegaly patient population includes 36,000 undiagnosed patients and 19,000 patients with no active treatment, highlighting significant market potential[8] - Preliminary net product revenue for Q2 2025 is expected to reflect strong adoption rates among patients and prescribers[9] - 81% of prior authorizations for Palsonify have a minimum duration of 300 days, indicating strong patient retention and commitment[9] - The company is actively pursuing market expansion strategies, including partnerships with specialty pharmacies and treatment centers[10] - Palsonify's phased launch aims to address a broader acromegaly patient population, with a focus on newly diagnosed and treatment-naïve patients[8] Atumelnant Clinical Development - Atumelnant shows a promising profile for treating Congenital Adrenal Hyperplasia (CAH), with over 750 weeks of cumulative patient exposure in clinical trials[14] - The company has engaged over 200 participants in the Atumelnant clinical development program, demonstrating significant interest and potential for future growth[14] - Atumelnant is currently in Phase 3 studies for the treatment of Congenital Adrenal Hyperplasia (CAH) and has demonstrated a rapid and sustained reduction of Androstenedione (A4) levels to normal[18] - The Phase 2 cohorts demonstrated normalization of A4 levels and improvement in clinical symptoms associated with CAH[18] - The company is conducting an open-label extension study to reflect real-life clinical management of CAH patients, allowing for flexibility in adjusting doses as necessary[23] - The company is focused on minimizing adverse effects related to glucocorticoid treatment, such as diabetes and weight gain, through the use of Atumelnant[18] Efficacy and Safety of Atumelnant - Phase 3 study design for Atumelnant is well-powered to achieve both glucocorticoid dose reduction and correction of hyperandrogenemia, enhancing confidence in its efficacy[14] - In Phase 2 studies, Atumelnant achieved a 67% reduction in A4 levels while maintaining glucocorticoid (GC) doses at physiologic levels, with 7 out of 8 patients reaching these levels by the end of treatment[22] - The investigational drug showed significant decreases in A4 levels across all dose cohorts, with reductions of 58% to 70% compared to baseline[20] - Atumelnant's dosing regimen includes a morning dose that has been shown to maintain robust A4 reduction while tapering GC doses[21] - The treatment aims to address hyperandrogenism symptoms, including infertility and excessive hair growth, while minimizing GC-related adverse effects[18] - Atumelnant continues to be well tolerated with no serious adverse events reported in Phase 2 studies, with a total of 38 participants enrolled[27] - In the OLE study, 7 participants treated for over 20 weeks showed no treatment-related severe adverse events, and 1 participant was treated for almost 6.5 years[27] - No hepatic transaminase adverse events were reported in Cohort 4 or the OLE study, reinforcing the safety profile of Atumelnant[30] Future Outlook and Catalysts - The company is poised to deliver multiple commercial and clinical catalysts in the next 24+ months, including FDA approvals and Phase 3 readouts[31] - The company aims to replicate the reduction of A4 levels while reducing glucocorticoid doses to physiological levels[30] - The Phase 2 data drives confidence in the Phase 3 study design and goals for Atumelnant[30] - The company plans to evaluate differences in A4 reduction between morning and evening dosing, with no observed differences to date[30] - The total patient exposure in the OLE study includes 25 participants, with varying doses of Atumelnant (8 at 40 mg, 14 at 80 mg, 3 at 120 mg)[27] - The company is actively enrolling subjects in the OLE study, with a total of 27 participants currently[27]

Core Insights - Crinetics has achieved significant milestones in 2025, marking it as a breakthrough year for the company [3] - The company successfully obtained approval for a broad label for Palsonify, aimed at treating acromegaly, coinciding with its PDUFA date [3] Company Development - Crinetics has evolved from discussing its first molecule, CRN808, to focusing on Palsonify and building a comprehensive pipeline and business [2] - The management emphasizes the transition from merely developing drugs to establishing a sustainable business model [2]

Crinetics Pharmaceuticals FY Conference Summary Company Overview - **Company**: Crinetics Pharmaceuticals (NasdaqGS:CRNX) - **Date of Conference**: January 13, 2026 - **Key Speaker**: Scott Struthers, CEO Core Industry and Company Insights Achievements and Developments - **Palsinify Approval**: Received broad label approval for Palsinify for the treatment of acromegaly on its PDUFA date, marking a significant milestone for the company [3][7] - **Successful Launch**: The launch of Palsinify has been successful, with over 200 patients enrolled in the last quarter and more than 125 unique prescribers involved [8][9] - **Pipeline Expansion**: Positive phase two data reported for atumelnant, with ongoing phase three studies for carcinoid syndrome and new compound 9682 in phase one/two studies for neuroendocrine tumors (NETs) [3][4] Financial Position - **Funding**: The company has approximately $1.4 billion in the bank, providing a solid foundation for operations through 2030 [4] - **Revenue Generation**: Achieved over $5 million in revenue last year, with expectations for growth as Palsinify gains market acceptance [11] Patient Engagement and Market Strategy - **Patient Services**: Implemented a comprehensive patient services program, including a Quick Start program to facilitate access to Palsinify [10][13] - **Market Access**: Focus on expanding prescriber base and activating patients who have previously settled with their conditions [34][35] - **Payer Engagement**: Strong efforts to communicate the value of Palsinify to payers, with CVS Caremark covering over 27 million lives [36][38] Pipeline and Future Prospects Palsinify and Acromegaly - **Market Potential**: There are approximately 36,000 patients with acromegaly in the U.S., with only 3,000 currently on standard care, indicating significant room for growth [14][15] - **Blockbuster Potential**: The CEO expressed confidence that Palsinify could become a blockbuster drug, aiming to help more than 5,000 patients per $1 billion in revenue [15] Atumelnant and CAH - **Clinical Development**: Atumelnant is positioned as a treatment for congenital adrenal hyperplasia (CAH), with promising phase two data showing significant reductions in adrenal androgens [20][25] - **Patient Population**: Approximately 12,000 patients in the U.S. are affected by CAH, with a focus on achieving normal hormone levels through treatment [25] 9682 and Neuroendocrine Tumors - **New Platform**: 9682 is being developed as a drug targeting agent for SST2-positive expressing solid tumors, with a phase 1/2 trial currently underway [27][28] - **Market Opportunity**: There are 11,000-21,000 patients currently treated for neuroendocrine tumors, with many more not receiving treatment [28] Key Milestones and Future Outlook - **2030 Vision**: The company aims to emerge as a premier endocrinology business with two marketed products and four approved indications by 2030 [30] - **Clinical Pipeline**: Anticipates having seven clinical pipeline candidates in development, with ongoing investments in discovery labs [30] Additional Insights - **Patient-Centric Approach**: Emphasis on patient stories and experiences to enhance engagement and support for Palsinify [12][13] - **Regulatory Strategy**: The company is actively monitoring and managing clinical trials to ensure high-quality data and compliance [45][46] This summary encapsulates the key points from the Crinetics Pharmaceuticals FY Conference, highlighting the company's achievements, pipeline developments, financial position, and strategic outlook for the future.

JANUARY 2026 Beyond Innovation to Impact: Building the Premier Endocrinology Business J.P. Morgan Healthcare Conference Angela Living with Acromegaly Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forw ...